TY - JOUR
AB - Reactions 1939, p205 - 14 Jan 2023 Left deep vein thrombosis: case report A 31-year-old woman developed left deep vein thrombosis (DVT) during contraceptive treatment with estradiol-congener- compounds/progesterone-congener-compounds. The woman had a medical history of severe congenital factor-XIII deficiency, diagnosed at the age of 5 years. She presented at the age of 31 years with a provoked left DVT of the popliteal vein. Several risk factors were taken into consideration involving long haul travel, oral contraception with estradiol-congener-compounds/progesterone-congener-compounds [estrogen-progestin; dosage, duration of treatment to reaction onset and outcome not stated] and cryoprecipitate infusions. A heterozygous factor-V Leiden mutation was detected on thrombophilia testing. At the age of 36 years, she had an uneventful pregnancy with enoxaparin sodium [enoxaparin] for venous thromboprophylaxis, administered throughout the pregnancy with concomitant supplementation of factor- XIII. At the age of 48 years, she experienced unprovoked DVT which was treated with rivaroxaban. Later at the age of 58 years, she exhibited an unprovoked pulmonary embolism in association with DVT of the left femoral vein, after 2 weeks of factor-XIII treatment. Eventually, it was decided to maintain a long-standing anticoagulation with rivaroxaban concomitantly along with factor- XIII. Bounaix L, et al. Recurrent venous thromboembolic disease in 
TI - Estradiol-congener-compounds/progesterone-congener-compounds
JO - Reactions Weekly
DO - 10.1007/s40278-023-31613-x
DA - 2023-01-01
UR - https://www.deepdyve.com/lp/springer-journals/estradiol-congener-compounds-progesterone-congener-compounds-UWsXnxXj6T
SP - 205
EP - 205
VL - 1939
IS - 1
DP - DeepDyve
ER -